EP2386269A3 — Naltrexone long acting formulations and methods of use
Assigned to Alkermes Inc · Expires 2012-04-25 · 14y expired
What this patent protects
The invention described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes describes long acting formulations of naltrexone, which achieve serum AUC values at least twice that of oral …
USPTO Abstract
The invention described herein arose from unexpected discoveries made during clinical trials with a long acting formulation of naltrexone. As such, the invention includes describes long acting formulations of naltrexone, which achieve serum AUC values at least twice that of oral administration.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.